title: Acute effects of sildenafil on uroflowmetric parameters in erectile dysfunction patients with and without lower urinary tract symptoms.
abstract: Using phosphodiesterase type 5 (PDE5) inhibitors in patients with lower  urinary tract symptoms continues to draw attention. Despite clinical  improvements in patients, it is still debatable whether urinary flow rates are  increased or not. The aim of this study was to evaluate the acute effects of  sildenafil, a PDE5 inhibitor, on uroflowmetry parameters. A total of 110 men  who had applied to our outpatient clinics and who had had no history of alpha  blocker and PDE5 inhibitor use were included in our study. Two uroflowmetries  were performed within 24-72 hours without any treatment. Participants  received 50 mg of sildenafil at their third visit, and uroflowmetry was  repeated after 2 hours. A total of 102 men were included in the analysis, and  baseline uroflowmetry values were compared with values obtained after  sildenafil use. The mean age of the 102 participants who had attended all  three visits (92.7%) was 52.1 ± 12.2 years. Mean of baseline maximal  flow rate values were 17.1 ± 5.1 mL/s, mean of baseline maximal flow  rate after sildenafil was 18.2 ± 5.1 mL/s; average flow rate values at  the baseline and after sildenafil were 9.5 ± 3.5 and 9.9 ± 3.5  mL/s, respectively. Means of postvoid residual urine volume for baseline and  after sildenafil were 31.2 ± 20.1 and 27.7 ± 18.4 mL,  respectively. Statistically significant difference is determined between  baseline and postsildenafil values in terms of average flow rates at baseline  and postvoid residual urine values. Results of this study suggest that  sildenafil has an effect on uroflowmetric parameters during an acute  period.
authors.affiliation: Department of Urology, Haydarpaşa Numune Training and Research Hospital, Istanbul, Turkey.
authors.forename: Metin I
authors.initials: MI
authors.lastname: Öztürk
authors.forename: Orhan
authors.initials: O
authors.lastname: Koca
authors.forename: Zülfü
authors.initials: Z
authors.lastname: Sertkaya
authors.forename: Muzaffer O
authors.initials: MO
authors.lastname: Keles
authors.forename: Cevdet
authors.initials: C
authors.lastname: Kaya
authors.forename: Muhammet I
authors.initials: MI
authors.lastname: Karaman
mesh_terms: D000328:Adult; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000188:drug therapy; D011687:Purines / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000627:therapeutic use*; D014554:Urination / Q000187:drug effects / Q000502:physiology*; D014563:Urodynamics / Q000187:drug effects*
chemical_list: D058986:Phosphodiesterase 5 Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate